Trial Profile
Phase 2 Study of Desensitization Protocol for Highly Sensitized Wait Listed Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Immunoglobulin G (Primary) ; Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 15 Jul 2016 New trial record